How to get a CE mark for a medical device the FDA has cleared: the 510(k) does not transfer, its test data and your quality system partly do, and the order of six steps and the speed of your answers decide how long European revenue waits.
Last updated: November 2026
In brief
- No transfer. A 510(k) does not carry over: to get a CE mark for a medical device in class IIa, IIb or III, Regulation (EU) 2017/745 (MDR) requires a certificate from an EU notified body.
- The clock. Counted from the first day of preparation, excluding any clinical investigation, a certificate takes 12 to 32 months on the quality-system route and 19 to 38 on the product route (CW1 Group calculation from two Commission surveys).
- The bill. Manufacturers reported median direct costs of €50,000 (about $54,800) for an initial quality-system certificate and €100,000 (about $109,700) per product certificate (data through October 2025).
- The order. Few applications are refused, but of the 524 refusal reasons notified bodies gave by February 2026, 254 concerned scope, classification or procedure (CW1 Group count).
Does FDA clearance count toward a CE mark?
Clearance by the U.S. Food and Drug Administration (FDA) counts as evidence and nothing more: under the MDR, devices in classes IIa, IIb and III need an EU notified body's certificate to carry the CE mark (Article 52). The class comes from the 22 rules of the MDR's Annex VIII, and the FDA's three classes do not carry over: Rule 8 puts surgical meshes, total or partial joint replacements and implants that touch the spinal column in class III, except for components such as screws and plates.
Devices certified under the MDR's predecessor directives have until the end of 2027 or 2028 to transition if they met 2024 deadlines and other conditions (Regulation (EU) 2023/607); a device arriving from the United States in 2027 has no such bridge.
The quality system travels best. Since February 2, 2026, the FDA's Quality Management System Regulation (QMSR) has incorporated ISO 13485:2016 by reference, yet a notified body will still audit the system against the MDR's own list of 13 aspects (Article 10(9)).
The evidence travels in part. Test reports carry over, though the EU file requires complete protocols and data analysis; clinical data are the bigger gap. By the FDA's own account, only a small percentage of 510(k)s require them, while the MDR requires clinical data for every device, barring justified exceptions. A U.S. study, such as an investigational device exemption (IDE) study, counts as a clinical investigation, weighed by whether it met the MDR's rules (Article 61(3)). The predicate stays behind: substantial equivalence allows different technological characteristics that raise no different questions of safety and effectiveness, while the MDR asks for similar technical, biological and clinical characteristics and access to the other device's data (Annex XIV).
Why do FDA-cleared devices stall on the way to a CE mark?
They stall twice: before the notified-body contract, when the steps come in the wrong order, and after it, in rounds of questions. Each European decision narrows the next: the class and, for an implant or a class III device, the MDR's exemption lists set the route and the depth of evidence, and the device type and route determine which notified bodies may take the file.
The notified bodies' figures, which cover all applicants, show where the order fails. Refusals are few: 989 of the 31,902 MDR applications submitted by February 28, 2026, in a survey for the European Commission. But of the 524 refusal reasons it tallied separately, sometimes several per application, 254, or 48% by CW1 Group's count, concerned the body's scope, the device's qualification or class, or the procedure, all settled before the file is written. Another 131 cited incomplete applications, and only 14 of the 52 bodies said that most submissions they receive are complete.
Why notified bodies refused MDR applications
Refusal reasons recorded up to February 28, 2026, in the survey's detailed data: 524 in all, and one application can have several. In its smaller dataset, 989 of the 31,902 MDR applications submitted had been refused.
The law sets part of the order. A manufacturer registers in EUDAMED, the European database on medical devices, and receives the single registration number (SRN) it needs to apply to a notified body (Article 31). For a company outside the EU, EUDAMED's guide adds a step: the registration names an EU Authorized Representative, which holds the company's mandate and verifies the request before the competent authority in the representative's country validates it. A missing mandate blocks the SRN and, with it, the application. Starting February 25, 2027, a notified body may quote only once it knows the representative and the device's purpose, characteristics and class, a rule meant to prevent refusals for incompleteness or scope (Implementing Regulation (EU) 2026/977, Article 1 and recital 5).
What do the two MDR routes cost in months and money?
Counted from the first day of preparation, an MDR certificate takes 12 to 32 months on the quality-system route and 19 to 38 months when a product certificate is added. That is CW1 Group's calculation from the Commission's surveys, using the two time ranges notified bodies cite most for each route, excluding any clinical investigation.
| Phase or cost | Quality-system route | Product route (quality system and product) |
|---|---|---|
| Devices | Class IIa; class IIb, including the implants on the list in Article 52(4), extended in July 2026 to dental implants, bone substitutes, nails, anchors, catheters and others | Class III, including surgical meshes, joint replacements and implants that touch the spinal column, except components such as screws and plates (Rule 8); class IIb implants not on that list |
| What the body reviews | The quality system, and the technical documentation of at least one representative device per category or generic device group | The quality system, and the technical documentation of every device, each with its own certificate |
| Clinical investigation | The default only for the implants on this route, unless the Article 61(6)(b) list or a full-access contract applies; otherwise needed where existing clinical data fall short | The default (Article 61(4)), unless the Article 61(6)(b) list or a full-access contract applies; it runs before the application |
| Preparing the application | 6 to 12 months for 44% of manufacturers | 6 to 12 months for 44% of manufacturers |
| Application to written agreement | Under 2 months for 65% of files, according to the bodies; over 3 months for 42% of manufacturers | Under 2 months for 65% of files, according to the bodies; over 3 months for 42% of manufacturers |
| Written agreement to certificate | 13 to 18 months for 62% of 47 notified bodies and 6 to 12 for 30%; more than 18 months for about 45% of 102 manufacturers | 13 to 18 months for 51% of 39 notified bodies and 19 to 24 for 31%; more than 19 months for 54% of 108 manufacturers |
| From the first day of preparation, excluding any clinical investigation (CW1 Group calculation) | 12 to 32 months; 25 or more for manufacturers reporting more than 18 months | 19 to 38 months; 25 or more for manufacturers reporting more than 19 months |
| Notified-body fees per initial certificate | €32,500 (€56,872) | €32,500 for the quality system, plus €50,000 (€83,782) per product certificate |
| Direct cost per initial certificate | €50,000 (€88,867) | €50,000, plus €100,000 (€194,785) per product certificate |
| Writing the clinical evaluation, per device | €20,000 (€32,774) in IIa; €40,000 (€50,697) in IIb | €50,000 (€77,446) in III; €28,500 (€75,007) for IIb implants |
| Maintenance per certificate, each year | €30,000 (€40,694) | €30,000 (€46,264) per product certificate, on top of the quality system's |
| One device, excluding any clinical investigation: certificates, clinical evaluation and a year of maintenance (CW1 Group sum) | €100,000 to €120,000 at the medians, about $109,700 to $131,600; €162,335 to €180,258 at the averages | €260,000 at the medians for class III, about $285,200; €448,056 at the averages |
Going by the bodies' answers, a certificate within 24 months of starting is mid-range on the quality-system route and fast on the product route, where the low end leaves five months of slack. Manufacturers report longer waits: about 45% of 102 took more than 18 months from contract to a quality-system certificate, and 54% of 108 more than 19 on the product route; with six months of preparation, either means 25 months or more.
If preparation starts in January 2027
Months from the first day of preparation to an MDR certificate, excluding any clinical investigation, and the dates they imply (CW1 Group calculation, for illustration). Dashed line: 24 months.
For agreements signed on or after February 25, 2027, Implementing Regulation (EU) 2026/977 caps the notified body's own time at 170 days from a complete application on the Annex IX route: 30 days to the contract, an audit of up to 120 days and a documentation review of up to 90 in parallel, if the audit program allows, then 20 days to decide. The total assumes the default start date, the day after signature. That cap alone is more than twice the FDA's own average time on a 510(k), 75.6 days for those accepted in fiscal 2025, in its August 2026 performance report. And the European clock stops while the company answers questions, normally up to four times in each review, so the caps guarantee no certificate date, and no survey has tested them yet.
Costs come before any European revenue. The median notified-body fees manufacturers reported for an initial quality-system certificate, €32,500 (about $35,600), are already above the FDA's fiscal 2027 fee for a 510(k), $28,653, or $7,163 for a small business, and each certificate then costs a median €30,000 a year to maintain.
How to get a CE mark for a medical device, step by step
A U.S. company gets there in six steps, in this order, and can take the first on its own.
- Classify under Annex VIII. Write down the rule, the class, the route it implies and whether Article 61(4) makes a clinical investigation the default. Under Rule 11, software that informs diagnostic or therapeutic decisions is at least class IIa, and IIb or III when those decisions could lead to serious deterioration of health, surgery, irreversible harm or death.
- Sign the Authorized Representative's mandate. Appoint a single EU Authorized Representative for the device group (Article 11) and name it in your EUDAMED registration. The representative must verify that your technical documentation and declaration of conformity exist and becomes jointly and severally liable with you for defective devices if you breach your obligations under Article 10.
- Shortlist notified bodies, then ask for quotations. In the Commission's NANDO database, keep only bodies designated for your device's codes under Implementing Regulation (EU) 2017/2185 (MDA or MDN for the device type, MDS and MDT for specific characteristics and technologies). In February 2026, 13 of the 52 had issued no certificate on the product route, so ask each how many devices like yours it has certified, and ask for a structured dialogue before applying. Starting February 25, 2027, the quotation must estimate timelines and costs, including typical surveillance and unannounced audits; agree on the start date, by default the day after signature. Apply to one body per procedure: you must declare any application withdrawn or refused elsewhere (Article 53).
- Choose the clinical evidence route. Test the predicate against the three groups of characteristics in Annex XIV. If it belongs to another company and your device is implantable or class III, equivalence spares you a clinical investigation only under a contract giving full, ongoing access to its technical documentation, and only if that device's clinical evaluation met MDR requirements (Article 61(5)); types on the Article 61(6)(b) list, extended in July 2026 to dental implants, bone substitutes, pacemaker leads and others, are exempt when their clinical data suffice and any common specification is met. For other devices, sufficient access to the other device's data replaces the contract, and a new investigation follows only where existing clinical data fall short (MDCG 2023-7).
- Close the quality-system gaps. Check the system against the 13 aspects of Article 10(9), including post-market clinical follow-up, UDI and vigilance.
- Complete the file, apply and manage the review. Submit only an application the body can call complete. Once the contract is signed, name one owner for the body's questions and set a deadline for each reply, since the European clock waits for your answers. Meanwhile, translate labels and instructions into each market's language (German in Germany and French in France for lay users) and line up the EU importer, which must check the CE mark, the representative and the UDI (Article 13), so that EUDAMED registration and the first shipment follow the certificate without delay.
| Step | What your FDA work already covers | What the EU adds | Owner | Typical blocker |
|---|---|---|---|---|
| 1. MDR classification | The device description and intended use; the FDA class, one of three, does not carry over | Four classes set by 22 rules (Annex VIII); the class and, for implants and class III devices, the lists in Articles 52(4) and 61(6)(b) fix the route and whether a clinical investigation is the default | Manufacturer | A wrong qualification or classification: 16% of refusal reasons |
| 2. EU Authorized Representative and EUDAMED | Annual FDA establishment registration; a UDI from GS1, HIBCC or ICCBBA, which the EU also designates | A sole representative under a written mandate, jointly and severally liable if you breach your obligations, with its own person responsible for regulatory compliance, separate from yours; actor registration and an SRN before applying; a Basic UDI-DI, assigned before applying for class III and for class IIb implants not on the Article 52(4) list, and device registration | Authorized Representative and manufacturer | No signed mandate: no SRN, so no application |
| 3. Notified body selection | No direct counterpart; 13 of the 15 MDSAP auditing organizations are EU notified bodies, according to a survey MedTech Europe and COCIR cited in February 2025 | A body designated for the device's codes (MDA, MDN, MDS, MDT); one application per procedure; starting February 25, 2027, quotations with costs and timelines, and notice of any increase above 10% | Manufacturer chooses; the notified body accepts | An application outside the body's designation: 30% of refusal reasons |
| 4. Clinical evaluation | Bench and any clinical data; IDE study results, assessed as clinical investigations | A clinical evaluation report based on clinical data (Article 61, Annex XIV); equivalence on technical, biological and clinical grounds with access to the data; a post-market clinical follow-up plan | Manufacturer; the notified body assesses | Another company's predicate: for implants and class III, a clinical investigation unless a full-access contract or the Article 61(6)(b) list applies |
| 5. QMS audit (QMSR vs. ISO 13485) | The QMSR has incorporated ISO 13485:2016 since February 2, 2026 | The 13 aspects of Article 10(9); a person responsible for regulatory compliance (Article 15), within the company unless it is a micro or small enterprise; an initial audit, surveillance at least every 12 months and an unannounced audit at least once every five years | Manufacturer; the notified body audits | Counting on FDA inspections or MDSAP reports: the EU is only an MDSAP observer |
| 6. Technical documentation | Test reports: engineering performance, sterility, EMC, software validation, biocompatibility | The structure of Annexes II and III, with complete protocols and data analysis; a post-market surveillance plan; labels and instructions in each market's language | Manufacturer; the notified body assesses | An incomplete application: 25% of refusal reasons |
The Commission's proposal of December 16, 2025, to revise the MDR would drop the full-access contract for equivalence and the five-year limit on certificates, but in November 2026 it still awaited a committee decision in the European Parliament: plans for 2027 rest on the rules in force.
How does CW1 Group work with medical device companies?
CW1 Group is a team of strategy and finance consultants who work with physicians, and it has companies in Gothenburg, Frankfurt and Covilhã. With medical device companies, it carries out the initial assessment, designs the strategy, prepares the path and does the first regulatory and financial work, and then the company continues on its own. CW1 Group does not issue certificates, which is the notified body's task, and does not act as an Authorized Representative.
Frequently asked questions
How do I get a CE mark if my device already has FDA 510(k) clearance?
Through an MDR conformity assessment, with an EU notified body for classes IIa, IIb and III, since the 510(k) does not transfer. Its test reports, your quality system and any clinical study results are your starting point.
What are the steps to CE mark a medical device under the EU MDR?
Six, in order: classify under Annex VIII; sign an EU Authorized Representative's mandate and obtain an SRN; shortlist notified bodies and ask for quotations; choose the clinical evidence route; close the quality-system gaps; then complete the file, apply and manage the review while preparing the launch.
Which parts of my FDA submission can I reuse for CE marking?
Most of the test evidence and the quality system: test reports with complete protocols, a QMSR quality system built on ISO 13485:2016, and U.S. clinical study results, assessed as clinical investigations. The FDA class and the predicate do not carry over.
How long does CE marking take after FDA clearance?
In February 2026, 82% of 39 notified bodies cited 13 to 24 months from the written agreement to a new certificate on the product route. From the first day of preparation and excluding any clinical investigation, CW1 Group's calculation gives 19 to 38 months on that route and 12 to 32 on the quality-system route.
Does an MDSAP audit replace the notified body's audit?
No. The European Union is only an official observer in the Medical Device Single Audit Program, and in February 2025 MedTech Europe and COCIR were still asking for MDSAP certificates to count toward CE marking. An MDSAP auditing organization that is also a notified body may combine the two audits.








